Role of P-glycoprotein and the intestine in the excretion of DPC 333 [(2R)-2-{(3R)-3-amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl] -2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide] in rodents

Drug Metabolism and Disposition

Volumn 36, Issue 6, 2008, Pages 1102-1110

  Garner, C Edwin ^a   Solon, Eric ^b   Lai, Chii Ming ^b   Lin, Jianrong ^a   Luo, Gang ^c   Jones, Kevin ^a   Duan, Jingwu ^c   Decicco, Carl P ^c   Maduskuie, Thomas ^f   Mercer, Stephen E ^c   Gan, Lian Shen ^d   Qian, Mingxin ^e   Prakash, Shimoga ^c   Shen, Huey Shin ^b   Lee, Frank W ^g  

^a ASTRAZENECA   (United Kingdom)

^b Quest Pharmaceutical Services   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e GENENTECH INC   (United States)

^f Pharmacokinetics Pharmacodynamics and Bioanalytical Sciences Genentech Inc ^*  (United States)

^g MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [3 AMINO 3 [4 (2 METHYLQUINOLIN 4 YLMETHOXY)PHENYL] 2 OXOPYRROLIDIN 1 YL] N HYDROXY 4 METHYLPENTANAMIDE; 2 [3 AMINO 3 [4 (2 METHYLQUINOLIN 4 YLMETHOXY)PHENYL] 2 OXOPYRROLIDIN 1 YL] N HYDROXY 4 METHYLPENTANAMIDE CARBON 14; ADENOSINE TRIPHOSPHATASE; BREAST CANCER RESISTANCE PROTEIN; CARBON 14; CYCLOSPORIN A; DPC 333; ELACRIDAR; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; RADIOPHARMACEUTICAL AGENT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; VERAPAMIL; VINBLASTINE;

ANIMAL CELL; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG PENETRATION; DRUG STRUCTURE; DRUG TRANSPORT; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE FUNCTION; MALE; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIOACTIVITY; RAT; SINGLE DRUG DOSE;

ANIMALS; CACO-2 CELLS; CELL LINE; DOGS; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED BALB C; P-GLYCOPROTEIN; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; TRANSFECTION;

MUS; RATTUS; RODENTIA;

EID: 44149096026     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.017038     Document Type: Article

References (44)

1. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH (1999) The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 59:4237-4241.
2. Artursson P, Ungell AL, and Lofroth JE (1993) Selective paracellular permeability in two models of intestinal absorption: cultured monolayers of human intestinal epithelial cells and rat intestinal segments. Pharm Res 10:1123-1129.
3. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, Schellens JH (2005) The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65:2577-2582.
4. Caldwell JH, Caldwell PB, Murphy JW, and Beachler CW (1980) Intestinal secretion of digoxin in the rat. Augmentation by feeding activated charcoal. Naunyn Schmiedebergs Arch Pharmacol 312:271-275.
5. Chang JH, Kochansky CJ, and Shou M (2006) The role of P-glycoprotein in the bioactivation of raloxifene. Drug Metab Dispos 34:2073-2078.
6. 14C]Daptomycin in rats. J Pharm Sci 83:1294-1299.
7. Dautrey S, Felice K, Petiet A, Lacour B, Carbon C, and Farinotti R (1999) Active intestinal elimination of ciprofloxacin in rats: modulation by different substrates. Br J Pharmacol 127:1728-1734.
8. de Bruin M, Miyake K, Litman T, Robey R, Bates SE (1999) Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 146:117-126.
9. Drüeke T, Hennessen U, Nabarra B, Ben Nasr L, Lucas PA, Dang P, Thomasset M, Lacour B, Coudrier E, and McCarron DA (1990) Ultrastructural and functional abnormalities of intestinal and renal epithelium in the SHR. Kidney Int 37:1438-1448.
10. Eisenblätter T, Hüwel S, Galla HJ (2003) Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier. Brain Res 971:221-31.
11. Fischer E, Rafiel A, and Bojcsev S (1995) Intestinal elimination of p-nitrophenol in the rat. Acta Physiol Hung 83:355-362.
12. Greiner B, Eichelbaum M, Fritz P, Kreichgauer H, Von Richter O, Zundler J, and Kroemer HK (1999) The role of intestinal p-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147-153.
13. Hall SD, Thummel KE, Watkins PB, Lown KS, Benet LZ, Paine MF, Mayo RR, Turgeon DK, Bailey DG, Fontana RJ, et al. (1999) Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 27:161-166.
14. Hassan NJ, Pountney DJ, Ellis C, Mossakowska DE (2006) BacMam recombinant baculovirus in transporter expression: a study of BCRP and OATP1B1. Protein Expr Purif 47:591-598.
15. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T (1993) In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53:4595-4602.
16. Hyde SC, Emsley P, Hartshorn MJ, Mimmack MM, Gileadi U, Pearce SR, Gallagher MP, Gill DR, Hubbard RE, and Higgins CF (1990) Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 346:362-365.
17. Imbert F, Jardin M, Fernandez C, Gantier JC, Dromer F, Baron G, Mentre F, Van Beijsterveldt L, Singlas E, Gimenez F (2003) Effect of efflux inhibition on brain uptake of traconazole in mice infected with Cryptococcus neoformans. Drug Metab Dispos 31:319-325.
18. Lagas JS, Vlaming ML, van Tellingen O, Wagenaar E, Jansen RS, Rosing H, Beijnen JH, and Schinkel AH (2006) Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin Cancer Res 15:6125-6132.
19. Leusch A, Volz A, Muller G, Wagner A, Sauer A, Greischel A, and Roth W (2002) Altered drug disposition of the platelet activating factor antagonist apafant in mdr1a knockout mice. Eur J Pharm Sci 16:119-128.
20. Li J, Zhou S, Huynh H, and Chan E (2005) Significant intestinal excretion, one source of variability in pharmacokinetics of COL-3, a chemically modified tetracycline. Pharm Res 22:397-404.
21. Mayer U, Wagenaar E, Beijnen JH, Smit JW, Meijer DKF, Van Asperen J, Borst P, and Schinkel AH (1996) Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a p-glycoprotein . Br J Pharmacol 119:1038-1044.
22. Merino G, Jonker JW, Wagenaar E, Pulido MM, Molina AJ, Alvarez AI, Schinkel AH (2005) Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2). Drug Metab Dispos 33:614-618.
23. Pang KS, Yuen V, Fayz S, te Koppele JM, and Mulder GJ (1986) Absorption and metabolism of acetaminophen by the in situ perfused rat small intestine preparation. Drug Metab Dispos 14:102-111.
24. Perdaems N, Caunes N, Canal P, and Chatelut E (1999) Possible excretion of etoposide via the intestinal mucosa. Cancer Chemother Pharmacol 43:520-521.
25. Qian M, Bai S, Brogdon B, Wu JT, Liu W, Covington M, Vaddi K, Newton RC, Deng Y, Garner CE, et al (2007) Pharmacokinetics and pharmacodynamics of DPC 333, a potent and selective inhibitor of tumor necrosis factor-α converting enzyme in rodents, dogs, chimpanzees and humans. Drug Metab Dispos 35:1916-1925.
26. Rabbaa L, Dautrey S, Colas-Linhart N, Carbon C, and Farinotti R (1996) Intestinal elimination of ofloxacin enantiomers in the rat: evidence of a carrier-mediated process. Antimicrob Agents Chemother 40:2126-2130.
27. Rafiei A, Bojcsev S, and Fischer E (1996) Dose-dependent intestinal and hepatic glucuronidation and sulfatation of p-nitrophenol in the rat. Acta Physiol Hung 84:333-335.
28. Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, Polli JW (2006) In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 34:786-792.
29. Salphati L and Benet LZ (1998) Effects of ketoconazole on digoxin absorption and disposition in rat. Pharmacology 56:308-313.
30. Sarkadi B, Price EM, Boucher RC, Germann UA, and Scarborough GA (1992) Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 267:4854-4858.
31. Smit JW, Schinkel AH, Muller M, Weert B, and Meijer DK (1998a) Contribution of the murine mdr1a p-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption. Hepatology 27:1056-1063.
32. Smit JW, Schinkel AH, Weert B, and Meijer DK (1998b) Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted. Br J Pharmacol 124:416-424.
33. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DK, Borst P, Nooijen WJ, Beijnen JH, and van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (taxol) caused by p-glycoprotein in the intestine. Proc Natl Acad Sci U S A 94:2031-2035.
34. Ullberg S (1954) Studies on the distribution and fate of 35S-labeled benzylpenicillin in the body. Acta Radiol Suppl 118:1-110.
35. Ungell AL, Nylander S, Bergstrand S, Sjoberg A, and Lennernas H (1998) Membrane transport of drugs in different regions of the intestinal tract of the rat. J Pharm Sci 87:360-366.
36. van Asperen J, van Tellingen O, and Beijnen J (2000) The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab Dispos 28:264-267.
37. Villanueva SS, Ruiz ML, Soroka CJ, Cai SY, Luquita MG, Torres AM, Sanchez Pozzi EJ, Pellegrino JM, Boyer JL, Catania VA, et al. (2006) Hepatic and extrahepatic synthesis and disposition of dinitrophenyl-S-glutathione in bile duct-ligated rats. Drug Metab Dispos 34:1301-1309.
38. Wang Y, Aun R, and Tse FL (1997) Absorption of D-glucose in the rat studied using in situ intestinal perfusion: a permeability index approach. Pharm Res 14:1563-1567.
39. Wang Y, Lin H, Tullman R, Jewell CF Jr, Weetall ML, and Tse FL (1999) Absorption and disposition of a tripeptoid and a tetrapeptide in the rat. Biopharm Drug Dispos 20:69-75.
40. Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, Fritz P, von Richter O, Warzok R, Hachenberg T, et al. (2000) Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther 68:345-355.
41. Yasuhara M, Kurosaki Y, Kimura T, and Sezaki H (1984) Drug elimination function of rat small intestine: metabolism and intraluminal excretion. Biochem Pharmacol 33:3131-3136.
42. Yeboah D, Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W (2006) Expression of breast cancer resistance protein (BCRP/ABCG2) in human placenta throughout gestation and at term before and after labor. Can J Physiol Pharmacol 84:1251-1258.
43. Zalups RK (1998) Intestinal handling of mercury in the rat: implications of intestinal secretion of inorganic mercury following biliary ligation or cannulation. J Toxicol Environ Health A 53:615-636.
44. Zhang Y, Gupta A, Wang H, Zhou L, Vethanayagam RR, Unadkat JD, and Mao Q (2005) BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm Res 22:2023-2034.